SYDNEY, AUSTRALIA--(Marketwired - Sep 11, 2013) - Prima BioMed Ltd (
The Company's presentation is scheduled to begin at 12:20 p.m. Central European Time on Monday, September 16, 2013 at the Warsaw Stock Exchange, Trading Floor.
About Prima BioMed
Prima BioMed is a globally active leader in the development of personalized bio-therapeutic products for cancer. Prima is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and to maximize value to shareholders. Prima's lead product is CVac™, an autologous dendritic cell-based product currently in clinical trials for ovarian cancer patients in remission and soon starting in trials for pancreatic, colorectal, and triple-negative breast cancers.